AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.

Employees

Sector

Drug Retailers

More about the company

End-of-day quote NORDIC GROWTH MARKET 2025-06-27			5-day change	1st Jan Change
0.7550 ^SEK	-1.82%		-2.58%	-0.40%

08-26	Acucort study published in scientific journal	FW
08-24	Acucort appoints Carl Frisk as Strategic Alliance Manager	FW

Market Cap	128M 13.43M 11.52M 10.82M 9.88M 18.64M 1.28B 18.73M 49.61M 646M 50.41M 49.32M 2.14B	P/E 2024	-3.61x	P/E 2025	-5x
Enterprise Value	101M 10.59M 9.09M 8.53M 7.79M 14.71M 1.01B 14.78M 39.14M 510M 39.78M 38.91M 1.69B	EV / Sales 2024	11.3x	EV / Sales 2025	17x
Free-Float	67.11%	Yield 2024 *	-	Yield 2025	-

08-26	Acucort study published in scientific journal	FW
08-24	Acucort appoints Carl Frisk as Strategic Alliance Manager	FW
08-19	Acucort lifts revenue in Q2	FW
08-19	AcuCort AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-11	Acucort's phase IV study with Zeqmelit published	FW
08-11	Acucort Publishes Results from Phase Iv Study with Zeqmelit Oral Film	CI
08-07	Acucort postpones interim report to August 19	FW
07-27	AcuCort Receives Renewed FDA Small Business Waiver Ahead of Planned NDA Submission	CI
07-27	AcuCort Renews US FDA Small Business Waiver for New Drug Applications	MT
07-27	FDA waives application fee for Acucort	FW
06-11	Acucort sees increased partner interest ahead of BIO Convention in the U.S.	FW
05-27	AcuCort CEO: Focus on strengthening presence in existing markets, developing new partnerships, and advancing in the US	FW
04-28	Acucort reports slight increase in operating loss	FW

08-26	AcuCort: AcuCort study on patient preferences published in peer-reviewed scientific journal	PU
08-26	AcuCort study on patient preferences published in peer-reviewed scientific journal	AQ
08-24	AcuCort: AcuCort appoints Carl Frisk as Strategic Alliance Manager	PU
08-24	AcuCort appoints Carl Frisk as Strategic Alliance Manager	AQ
08-11	AcuCort : first Phase IV study is now published	PU

AcuCort AB Stock NORDIC GROWTH MARKET

Stocks

ACUC

SE0009695927

Drug Retailers

Valuation : AcuCort AB

Latest news : AcuCort AB

Press Releases : AcuCort AB

Quotes and Performance

Managers and Directors : AcuCort AB

Other Drug Retailers

Financials

Company Profile

Manager	Title	Age	Since
Jonas Jonas Jönmark CEO	Chief Executive Officer	55	2020-08-08
Anna Cherouvrier Hansson PRN	Corporate Officer/Principal	53	2025-10-13

Director	Title	Age	Since
Anna Maria Albertina Eriksrud BRD	Director/Board Member	68	2017-02-07
Ebba Cecilia Fåhraeus CHM	Chairman	63	2017-12-31
Göran Tornling BRD	Director/Board Member	79	2020-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACUCORT AB	-1.82%	-2.58%	-	-	13.43M
JD HEALTH INTERNATIONAL INC.	-1.50%	-5.55%	-43.82%	-15.73%	15.18B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-1.56%	-3.38%	-44.73%	-30.88%	6.59B
MATSUKIYOCOCOKARA & CO.	-0.04%	+2.32%	-15.87%	-6.93%	6.37B
YIFENG PHARMACY CHAIN CO., LTD.	+0.63%	-0.83%	-1.37%	-23.02%	4.28B
NAHDI MEDICAL COMPANY	-0.37%	+0.97%	-20.42%	-39.42%	3.26B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+6.05%	+2.79%	+7.60%	-30.21%	3.09B
CLICKS GROUP LIMITED	-0.01%	-4.27%	-47.14%	-27.72%	2.92B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+0.72%	-2.39%	-15.29%	-5.20%	2.59B
GUARDIAN PHARMACY SERVICES, INC.	-0.37%	-0.21%	+45.19%	-	2.37B
Average	+0.15%	-0.70%	-15.10%	-22.39%	5.18B
Weighted average by Cap.	-0.27%	-1.42%	-25.29%	-20.36%

	2024	2025
Net sales	7.72M 809K 695K 652K 596K 1.12M 77.2M 1.13M 2.99M 38.95M 3.04M 2.97M 129M	6.68M 701K 602K 565K 516K 973K 66.86M 978K 2.59M 33.73M 2.63M 2.57M 112M
Net income	-17.4M -1.82M -1.57M -1.47M -1.34M -2.53M -174M -2.55M -6.74M -87.81M -6.85M -6.7M -291M	-26.19M -2.75M -2.36M -2.21M -2.02M -3.81M -262M -3.83M -10.15M -132M -10.31M -10.09M -438M
Net Debt	-2.77M -291K -250K -234K -214K -404K -27.73M -406K -1.07M -13.99M -1.09M -1.07M -46.34M	-27.01M -2.83M -2.43M -2.28M -2.08M -3.93M -270M -3.95M -10.47M -136M -10.64M -10.41M -452M